REGENXBIO amends AbbVie deal; restructures $200M milestones, starts DR pivotal; Q2 net loss $70.9M

REGENXBIO Inc.

Amendment to AbbVie collaboration: $100M milestone upon first pt dosed in Phase IIb/III DR trial, additional $100M upon first pt in Phase III.
REGENXBIO to pay costs for Phase IIb of that trial; AbbVie to fund new Phase III wAMD study (ACHIEVE).
Q2 net loss $70.9M ($1.38/share) vs $53.0M loss year ago; revenue $21.4M, down from $22.3M.
Cash $363.6M at June 30, 2025; expects to fund operations into early 2027.
RGX-202 Duchenne pivotal enrollment accelerated, to complete Oct 2025; topline data 1H 2026.

item 1.01item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.